A share price of Karyopharm Therapeutics Inc [KPTI] is currently trading at $1.34, up 5.51%. An important factor to consider is whether the stock is rising or falling in short-term value. The KPTI shares have gain 0.75% over the last week, with a monthly amount drifted -7.59%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, April 2024, Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of March 31, 2024 (the “Grant Date”) pursuant to the Company’s 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on January 19, 2023, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $8. Previously, RBC Capital Mkts upgraded its rating to Outperform on November 04, 2022, and elevated its price target to $10. On February 09, 2022, upgrade upgraded it’s rating to Neutral but maintained its price target of $8 on the stock. SVB Leerink downgraded its rating to a Mkt Perform but $6 remained the price target by the analyst firm on August 06, 2021. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 06, 2021, and downed its price target to $8. In a note dated August 06, 2021, JP Morgan downgraded an Neutral rating on this stock.
Karyopharm Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.62 and $4.87. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $1.34 at the most recent close of the market. An investor can expect a potential return of 571.64% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
Trailing Twelve Months sales for Karyopharm Therapeutics Inc [NASDAQ:KPTI] were 146.03M which represents 0.50% growth. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.89%, Pretax Profit Margin comes in at -0.98%, and Net Profit Margin reading is -0.98%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is 1.62 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2867 points at the first support level, and at 1.2333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3667, and for the 2nd resistance point, it is at 1.3933.
Karyopharm Therapeutics Inc [KPTI] reported earnings per share of -$0.36 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.31/share, meaning a difference of -$0.05 and a surprise factor of -16.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.3 per share as compared to estimates of -$0.28 per share, a difference of -$0.02 representing a surprise of -7.10%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Karyopharm Therapeutics Inc [NASDAQ:KPTI] is 3.37. On the other hand, the Quick Ratio is 3.32, and the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 1.06.
Transactions by insiders
Recent insider trading involved Paulson Richard A., President and CEO, that happened on Apr 04 ’24 when 3563.0 shares were sold. President and CEO, Paulson Richard A. completed a deal on Mar 05 ’24 to sell 3573.0 shares. Meanwhile, President and CEO Paulson Richard A. sold 19374.0 shares on Mar 01 ’24.
